View on GitHub

Added entries:

  • (FDA) FGFR2 rearrangements and sensitivity to futibatinib in intrahepatic cholangiocarcinoma.

Revised entries:

  • (Clinical evidence) SPOP variants and favorable prognosis in prostate adenocarcinoma was changed to sensitivity to abiraterone. Additionally, the doi url was revised to correctly point to the citation.